<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>From May 1989 to March 1991 60 bone marrow transplants were performed--41 allogeneic and 19 autologous--in patients with malignant and nonmalignant hemopathies and <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The transplant related mortality was 19.4% and 10.5% for allografts and autografts, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>The projected relapse free survival at 22 months in patients with malignant hemopathies who underwent allotransplantation in early phase was 81% and, in patients in advanced phase 21.4% (p less than 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain>In patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> the actuarial survival at 22 months is 60% </plain></SENT>
<SENT sid="4" pm="."><plain>In autografted patients, only one failed to have full engraftment and is dependent on platelet support at day 79 </plain></SENT>
<SENT sid="5" pm="."><plain>Follow-up in <z:hpo ids='HP_0000001'>all</z:hpo> autografts is less than one year </plain></SENT>
<SENT sid="6" pm="."><plain>These preliminary results of our bone marrow transplant program show low morbidity and mortality related to transplantation and suggest significant therapeutic effect </plain></SENT>
</text></document>